Epithalon (also known as Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Professor Vladimir Khavinson and colleagues. It was designed as a simplified, more stable analog of the natural pineal gland peptide Epithalamin, which is a complex polypeptide extract. The research originated from studies on the aging pineal gland and its role in regulating biological rhythms and longevity. Epithalon represents a significant effort in peptide biochemistry to isolate and replicate the bioactive components of natural gland extracts for experimental study. Its significance lies primarily in its role as a research tool for investigating the modulation of telomerase activity, cellular aging, and the potential influence on lifespan in model organisms, positioning it as a key compound in the field of experimental gerontology.
Quick Facts
| Also Known As | Epitalon, Ala-Glu-Asp-Gly, AEDG peptide |
|---|---|
| Sequence | Ala-Glu-Asp-Gly |
| Molecular Formula | C14H23N5O9 |
| Molecular Weight | 391.35 Da |
Research Parameters
| Half-Life | Unknown |
|---|---|
| Stability | Lyophilized powder is stable for extended periods when stored properly. After reconstitution in aqueous solvent, stability data is not well-established in public literature; typical research practice suggests storage at 2-8°C for short-term use (e.g., several days). |
| Solubility | Recommended reconstitution solvent for research is sterile water or bacteriostatic water. |
| Storage (Lyophilized) | -20°C, protect from light and moisture. |
| Storage (Reconstituted) | 2-8°C for short-term use; precise duration not standardized. |
| Typical Research Dose | 0.1-10 mcg per animal (model-dependent) |
| Cycle Parameters | Daily administration for extended periods (e.g., months) in lifespan studies; specific cycle protocols (on/off) are not commonly defined in research. |
| Amino Acid Count | 4 |
Mechanism of Action
The primary proposed mechanism of action for Epithalon involves the modulation of telomerase activity and interaction with genetic expression related to aging and cellular senescence. Research suggests it may influence the pineal gland's regulatory functions.
Telomerase Activation Pathway: Epithalon has been reported in experimental studies to stimulate telomerase activity in various human cell cultures, including fibroblasts and retinal pigment epithelial cells. This activation is thought to potentially slow the shortening of telomeres, which are protective caps at the ends of chromosomes that shorten with each cell division and are associated with cellular aging.
Gene Expression Modulation: Studies indicate Epithalon may influence the expression of genes involved in cell cycle regulation, senescence, and stress response. It has been associated with changes in the expression of p53, a key tumor suppressor and senescence regulator, and other aging-related genes in experimental models.
Pineal Gland Interaction: As an analog of a pineal peptide, Epithalon is theorized to interact with or mimic signals from the pineal gland, which is a master regulator of circadian rhythms and endocrine function. This interaction may indirectly affect systemic aging processes through hormonal and rhythmic pathways, although the precise receptor or signaling mechanism remains unidentified.
Research Applications
Experimental Gerontology: In animal models, particularly in rodents, Epithalon administration has been associated with extended average lifespan, improved physiological parameters of aging, and delayed onset of age-related pathologies. Research focuses on its potential to modulate the rate of biological aging.
Cellular Senescence Studies: In vitro research using human cell cultures has investigated Epithalon's effects on telomere length maintenance, telomerase activity, and markers of cellular senescence. It serves as a tool to study the molecular biology of aging in controlled laboratory settings.
Ophthalmic Research: Some experimental studies have explored the peptide's effects on age-related retinal conditions, noting potential influences on the viability and function of retinal pigment epithelial cells, which are crucial for retinal health.
Safety & Side Effects
From available animal studies, Epithalon has not been reported to cause significant acute toxicity or adverse side effects at the researched doses. Long-term administration in rodent models did not show increases in tumor incidence or major organ toxicity compared to controls. Anecdotally, no common side effects are reported in the research literature. Theoretical concerns would relate to the unknown consequences of prolonged telomerase activation in certain cell types, but this remains a speculative risk based on biological principles, not observed experimental data.
Dosage Information
All information is derived from published research studies and is for scientific reference only. Not for human therapeutic use.
Typical research doses in animal studies (e.g., mice, rats) range from 0.1 mcg to 10 mcg per animal per day, often administered via subcutaneous or intraperitoneal injection. In some in vitro cell culture studies, concentrations used range from nanomolar to micromolar levels added to the culture medium. Frequency is typically daily administration in animal longevity studies, with durations extending from several weeks to months, correlating with the lifespan of the model organism.
References
Khavinson, V. K., et al. 'Peptide regulation of cell differentiation.' Bulletin of Experimental Biology and Medicine, 2000.
Anisimov, V. N., et al. 'Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice.' Mechanisms of Ageing and Development, 2002.
Khavinson, V. K., et al. 'Epitalon peptide induces telomerase activity and telomere elongation in human somatic cells.' Bulletin of Experimental Biology and Medicine, 2003.
Anisimov, V. N., et al. 'Effects of the pineal gland peptide Epitalon on the life span and tumor incidence in rats.' Advances in Gerontology, 2004.
Kozina, L. S., et al. 'Antioxidant properties of the peptide Epitalon.' Bulletin of Experimental Biology and Medicine, 2007.
Khavinson, V. K., & Mikhailova, O. N. 'Peptides and aging.' Neuroendocrine Immunology, 2010.